Gemin X raises $8M for cancer R&D; Bruce Montgomery ready to open a new chapter in biotech career;

 @FierceBiotech: Early-stage deals are getting a lot sweeter for biotechs. Article  Follow @FierceBiotech

 @JohnCFierce: After seeing its lead therapy naproxcinod rebuffed at the FDA, France's NicOx says it will shutter its U.S. HQ. Report | Follow @JohnCFierce

> Gemin X Pharmaceuticals has raised $8 million in a Series E, which is earmarked to back its work on new cancer therapies. The round was led by Caxton Advantage Life Sciences Fund of New York and  Sanderling Venture Partners. Story

> Scientists working on chronic stress vaccine. News

> Dendreon: Provenge on course to hit blockbuster goal. Article

Xconomy reports that the well-known Seattle biotech entrepreneur and drug developer Bruce Montgomery has decided to hang up his spurs at Gilead and take some time out as he starts to scout for a new biotech opportunity. One possible option: Launch a new company. Report

> Princeton, NJ-based Signum Biosciences has named Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as its new CEO. Shroot replaces Dr. Gregory Stock who will remain as a member of the board. Release

> FDA calls out AMPAC on sketchy reply to warning. Item

And Finally... A protein malfunction has been linked to a form of mental retardation that affects up to one out of every 500 males. Release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.